Keywords: thai, drugmakers, view, cost, ppa, ban, thailand
Thai drugmakers view cost of PPA ban
Article | 11 December 2000
Thailand's pending ban on the sale of 493 cold remedies containingphenylpropanolamine (Marketletters passim) could cost the country's drug industry 300-400 million ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
